MASLD, Multimorbidity, and Mortality: Insights from the UK Biobank Study

Overview

This large UK Biobank study found that nearly 30% of participants had MASLD, which was associated with a higher prevalence of multimorbidity and a 16% increased risk of all-cause mortality. The presence of multiple long-term conditions further amplified mortality risk in both MASLD and non-MASLD populations.

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) affects about one third of the global population and is characterized by liver steatosis with cardiometabolic risk factors. MASLD ranges from simple steatosis to advanced liver disease and is linked to significant hepatic morbidity and mortality. Multimorbidity, defined as having two or more long-term conditions (LTCs), worsens health outcomes and mortality but has been understudied in MASLD populations. Understanding the interplay between MASLD, multimorbidity, and mortality is critical for improving clinical management and reducing healthcare burdens.

Data Highlights

Key Findings

• MASLD was present in 29.9% of the UK Biobank cohort at baseline.
• Individuals with MASLD had a higher prevalence of multimorbidity (21.3%) compared to those without MASLD (14.4%).
• MASLD was strongly associated with multiple long-term conditions, including metabolic, cardiovascular, cancer, kidney, mental/behavioral, and respiratory diseases.
• MASLD was linked to a 16% increased risk of all-cause mortality (HR 1.16), with stronger effects observed in females and those with fewer LTCs (≤3).
• Each additional LTC increased mortality risk by 30% in MASLD individuals and by 38% in non-MASLD individuals.
• Sixteen of the 47 studied LTCs were associated with increased mortality in people with MASLD.

Clinical Implications

Clinicians should recognize MASLD as a marker of increased extrahepatic multimorbidity and elevated mortality risk. Comprehensive assessment and management of coexisting long-term conditions are essential to improve outcomes in patients with MASLD. Targeted interventions addressing both liver disease and multimorbidity may reduce healthcare burdens and mortality.

Conclusion

MASLD significantly increases the prevalence of extrahepatic multimorbidity and all-cause mortality. Addressing the complex interplay between MASLD and multiple long-term conditions is critical for improving patient prognosis and reducing the public health impact of this common liver disease.

References

1. Rinella et al 2023 -- Definition and Clinical Implications of MASLD
2. UK Biobank 2006-2010 -- Cohort Description and Data Collection